90 related articles for article (PubMed ID: 28445619)
1. mTOR inhibitors and risk of chronic antibody-mediated rejection after kidney transplantation: where are we now?
Grimbert P; Thaunat O
Transpl Int; 2017 Jul; 30(7):647-657. PubMed ID: 28445619
[TBL] [Abstract][Full Text] [Related]
2. Calcineurin and mTOR inhibitors in kidney transplantation: integrative metamodeling on transplant survival and kidney function.
Khalid H; Fareed MM; Dandekar T; Shityakov S
Int Urol Nephrol; 2024 Apr; 56(4):1403-1414. PubMed ID: 37751051
[TBL] [Abstract][Full Text] [Related]
3. Effect of Calcineurin Inhibitors and Mammalian Target of Rapamycin Inhibitors on the Course of COVID-19 in Kidney Transplant Recipients.
Hasbal NB; Turgut D; Gok Oguz E; Ulu S; Gungor O
Ann Transplant; 2021 Mar; 26():e929279. PubMed ID: 33707409
[TBL] [Abstract][Full Text] [Related]
4. Utility of Routine Post Kidney Transplant Anti-HLA Antibody Screening.
Salhi S; Congy-Jolivet N; Hebral AL; Esposito L; Vieu G; Milhès J; Kamar N; Del Bello A
Kidney Int Rep; 2024 May; 9(5):1343-1353. PubMed ID: 38707794
[TBL] [Abstract][Full Text] [Related]
5. Feasibility of Interleukin-6 Receptor Blockade in Cardiac Antibody-mediated Rejection.
Pottebaum AA; January SE; Liu C; Lavine S; Schilling JD; Lavine KJ
Transplantation; 2024 Feb; 108(2):539-544. PubMed ID: 37638881
[TBL] [Abstract][Full Text] [Related]
6. Systemic meta-analysis assessing the short term applicability of early conversion to mammalian target of rapamycin inhibitors in kidney transplant.
Kumar J; Reccia I; Kusano T; Julie BM; Sharma A; Halawa A
World J Transplant; 2017 Apr; 7(2):144-151. PubMed ID: 28507917
[TBL] [Abstract][Full Text] [Related]
7. Donor-Specific Anti-Human Leukocyte Antigens Antibodies, Acute Rejection, Renal Function, and Histology in Kidney Transplant Recipients Receiving Tacrolimus and Everolimus.
Ferreira A; Felipe C; Cristelli M; Viana L; Basso G; Stopa S; Mansur J; Ivani M; Bessa A; Ruppel P; Aguiar W; Campos E; Gerbase-DeLima M; Proença H; Tedesco-Silva H; Medina-Pestana J
Am J Nephrol; 2017; 45(6):497-508. PubMed ID: 28511172
[TBL] [Abstract][Full Text] [Related]
8. CMV and BKPyV Infections in Renal Transplant Recipients Receiving an mTOR Inhibitor-Based Regimen Versus a CNI-Based Regimen: A Systematic Review and Meta-Analysis of Randomized, Controlled Trials.
Mallat SG; Tanios BY; Itani HS; Lotfi T; McMullan C; Gabardi S; Akl EA; Azzi JR
Clin J Am Soc Nephrol; 2017 Aug; 12(8):1321-1336. PubMed ID: 28576905
[TBL] [Abstract][Full Text] [Related]
9. Immunosuppressive agents in adult kidney transplantation in the National Health Service: a model-based economic evaluation.
Snowsill TM; Moore J; Mujica Mota RE; Peters JL; Jones-Hughes TL; Huxley NJ; Coelho HF; Haasova M; Cooper C; Lowe JA; Varley-Campbell JL; Crathorne L; Allwood MJ; Anderson R
Nephrol Dial Transplant; 2017 Jul; 32(7):1251-1259. PubMed ID: 28873970
[TBL] [Abstract][Full Text] [Related]
10. Emerging drugs for prevention of T-cell mediated rejection in liver and kidney transplantation.
Wong TC; Lo CM; Fung JY
Expert Opin Emerg Drugs; 2017 Jun; 22(2):123-136. PubMed ID: 28503959
[TBL] [Abstract][Full Text] [Related]
11. Autophagy in kidney transplants of sirolimus treated recipients.
Bhayana S; Baisantry A; Kraemer TD; Wrede C; Hegermann J; Bräsen JH; Bockmeyer C; Ulrich Becker J; Ochs M; Gwinner W; Haller H; Melk A; Schmitt R
J Nephropathol; 2017 Mar; 6(2):90-96. PubMed ID: 28491859
[TBL] [Abstract][Full Text] [Related]
12. Impact of Non-Human Leukocyte Antigen-Specific Antibodies in Kidney and Heart Transplantation.
Zhang X; Reinsmoen NL
Front Immunol; 2017; 8():434. PubMed ID: 28450866
[TBL] [Abstract][Full Text] [Related]
13. Donor-Specific Antibodies in Kidney Transplant Recipients.
Zhang R
Clin J Am Soc Nephrol; 2018 Jan; 13(1):182-192. PubMed ID: 28446536
[TBL] [Abstract][Full Text] [Related]
14. Treatment of chronic antibody mediated rejection with intravenous immunoglobulins and rituximab: A multicenter, prospective, randomized, double-blind clinical trial.
Moreso F; Crespo M; Ruiz JC; Torres A; Gutierrez-Dalmau A; Osuna A; Perelló M; Pascual J; Torres IB; Redondo-Pachón D; Rodrigo E; Lopez-Hoyos M; Seron D
Am J Transplant; 2018 Apr; 18(4):927-935. PubMed ID: 28949089
[TBL] [Abstract][Full Text] [Related]
15. Everolimus with cyclosporine withdrawal or low-exposure cyclosporine in kidney transplantation from Month 3: a multicentre, randomized trial.
Budde K; Zeier M; Witzke O; Arns W; Lehner F; Guba M; Jacobi J; Kliem V; Reinke P; Hauser IA; Vogt B; Stahl R; Rath T; Duerr M; Paulus EM; May C; Porstner M; Sommerer C;
Nephrol Dial Transplant; 2017 Jun; 32(6):1060-1070. PubMed ID: 28605781
[TBL] [Abstract][Full Text] [Related]
16. Influence of CYP3A4 and CYP3A5 polymorphisms on tacrolimus and sirolimus exposure in stable kidney transplant recipients.
Tamashiro EY; Felipe CR; Genvigir FDV; Rodrigues AC; Campos AB; Hirata RDC; Tedesco-Silva H; Medina-Pestana JO
Drug Metab Pers Ther; 2017 May; 32(2):89-95. PubMed ID: 28593920
[TBL] [Abstract][Full Text] [Related]
17. Recommendations for the use of everolimus in de novo kidney transplantation: False beliefs, myths and realities.
Pascual J; Diekmann F; Fernández-Rivera C; Gómez-Marqués G; Gutiérrez-Dalmau A; Pérez-Sáez MJ; Sancho-Calabuig A; Oppenheimer F
Nefrologia; 2017; 37(3):253-266. PubMed ID: 28551032
[TBL] [Abstract][Full Text] [Related]
18. Supplementary Administration of Everolimus Reduces Cardiac Systolic Function in Kidney Transplant Recipients.
Tsujimura K; Ota M; Chinen K; Nagayama K; Oroku M; Nishihira M; Shiohira Y; Abe M; Iseki K; Ishida H; Tanabe K
Ann Transplant; 2017 May; 22():315-322. PubMed ID: 28546531
[TBL] [Abstract][Full Text] [Related]
19. Cutaneous Toxicities From Transplantation-Related Medications.
Ilyas M; Colegio OR; Kaplan B; Sharma A
Am J Transplant; 2017 Nov; 17(11):2782-2789. PubMed ID: 28452165
[TBL] [Abstract][Full Text] [Related]
20. Future developments in kidney transplantation.
Viklicky O; Novotny M; Hruba P
Curr Opin Organ Transplant; 2020 Feb; 25(1):92-98. PubMed ID: 31833964
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
